Dyslipidemias
📧 Sign up to get email alerts when something new happens for Dyslipidemias.
Sign up freeTop drugs studied for this disease
-
EMA approval · 2026-08-06EMA Authorised: Cholib (fenofibrate;simvastatin) — Viatris Healthcare Limited
Cholib, a fixed-dose combination of fenofibrate and simvastatin, has been authorised for dyslipidemias in the European Union.
-
CLINICAL_TRIALS trial_result · 2026-04-27Clinical Trial Update: The Efficacy and Safety of Triple Therapy of Telmisartan/Amlodipine/Rosuvastatin [Phase 4]
Phase 4 trial update on the efficacy and safety of triple therapy telmisartan/amlodipine/rosuvastatin for hypertension and dyslipidemias.
-
CLINICAL_TRIALS trial_result · 2026-04-14Clinical Trial Update: Cluster Randomized Trial of a Digital Quality Improvement Intervention on LDLCholesterol Control [NA]
A completed cluster randomized trial evaluating a digital quality improvement intervention aimed at improving LDL cholesterol control in peo…
-
CLINICAL_TRIALS trial_result · 2026-04-14Clinical Trial Update: Bialystok Exercise Study in Diabetes [NA]
Medical University of Bialystok reports that the Bialystok Exercise Study in Diabetes has completed, evaluating exercise effects in people w…
-
CLINICAL_TRIALS trial_result · 2026-04-13Clinical Trial Update: Dachundou No Sugar Added Soymilk for Lipid Modulation [NA]
A completed clinical trial from National Taiwan Sport University evaluating Dachundou No Sugar Added Soymilk for lipid modulation in individ…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS research · 2026-04-09Clinical Trial Update: Impact of Obicetrapib and Obicetrapib Plus Repatha on Lp(a) Levels [Phase 2]
Phase 2 trial evaluating obicetrapib alone and with Repatha (evolocumab) for lowering lipoprotein(a) levels in dyslipidemias; currently recr…
-
EMA approval · 2026-03-13EMA Authorised: Vazkepa (Icosapent ethyl) — Recordati Industria Chimica e Farmaceutica S.p.A.
EMA authorised Vazkepa (icosapent ethyl) for the treatment of dyslipidemias; the marketing authorization holder is Recordati Industria Chimi…
-
EMA approval · 2026-03-04EMA Authorised: Leqvio (inclisiran) — Novartis Europharm Limited
The European Medicines Agency authorised Leqvio (inclisiran) from Novartis Europharm Limited for hypercholesterolemia and dyslipidemias, wit…
-
CLINICAL_TRIALS research · 2026-03-04Clinical Trial Update: PILI 'Āina Household [NA]
The PILI 'Āina Household trial, sponsored by the University of Hawaii, is currently recruiting participants. It targets Type 2 Diabetes and …
-
CLINICAL_TRIALS research · 2026-03-04Clinical Trial Update: 'Ai Pono Cooking Demonstrations [NA]
An ongoing University of Hawaii trial is recruiting participants for Ai Pono cooking demonstrations addressing Type 2 Diabetes, Hypertension…
-
EMA approval · 2026-02-27EMA Authorised: Nilemdo (bempedoic acid) — Daiichi Sankyo Europe GmbH
The European Medicines Agency authorised Nilemdo (bempedoic acid) for hypercholesterolemia and related dyslipidemias. The marketing authoris…
-
EMA approval · 2026-02-27EMA Authorised: Nustendi (bempedoic acid;ezetimibe) — Daiichi Sankyo Europe GmbH
The EMA has authorised Nustendi, a fixed-dose combination of bempedoic acid and ezetimibe, for hypercholesterolemia and related dyslipidemia…
-
CLINICAL_TRIALS trial_result · 2026-01-09Clinical Trial Update: Efficacy and Safety of Cipros 20 Association on Dyslipidemia Treatment [Phase 3]
Phase 3 clinical trial results show efficacy and safety data for Cipros 20 Association in treating dyslipidemias.
-
CLINICAL_TRIALS trial_result · 2025-12-24Clinical Trial Update: Study of ARO-ANG3 in Healthy Volunteers and in Dyslipidemic Patients [Phase 1]
Phase 1 study of ARO-ANG3 in healthy volunteers and dyslipidemic patients has completed; the update provides status of the trial.
-
CLINICAL_TRIALS research · 2025-12-22Clinical Trial Update: Evaluation of Milk Polar Lipids in Dyslipidemic Adults With Abdominal Obesity [EARLY_Phase 1]
Early-phase clinical trial evaluating milk polar lipids in adults with dyslipidemia and abdominal obesity; currently recruiting.
-
EMA approval · 2025-12-16EMA Authorised: Cholib (fenofibrate;simvastatin) — Viatris Healthcare Limited
The EMA has authorised Cholib, a fixed-dose combination of fenofibrate and simvastatin, for dyslipidemias.
-
EMA approval · 2025-12-15EMA Authorised: Repatha (Evolocumab) — Amgen Europe B.V.
EU regulators authorised Repatha (evolocumab) for dyslipidemias and hypercholesterolemia; decision date 12/12/2025.
-
CLINICAL_TRIALS trial_result · 2025-11-24Clinical Trial Update: A Phase III Long Term Study of K-877 Extended Release Tablet [Phase 3]
A Phase III long-term study of K-877 Extended Release Tablet for dyslipidemias has completed.
-
CLINICAL_TRIALS research · 2025-11-12Clinical Trial Update: Military Health and Nutrition Examination Study
A Pennington Biomedical Research Center-led clinical study is currently recruiting to investigate the relationships among hypertension, type…
-
CLINICAL_TRIALS trial_result · 2025-10-06Clinical Trial Update: A Clinical Pharmacology Study of K-877 Controlled Release Tablet [Phase 2]
A completed Phase 2 clinical pharmacology study of the controlled-release tablet form of K-877 (pemafibrate) for dyslipidemias.
-
CLINICAL_TRIALS trial_result · 2025-09-26Clinical Trial Update: A Quality Improvement Process to Support Delivery of Cardiovascular Care in Community Mental Health Organizations [NA]
This clinical trial update reports the completion of a Johns Hopkins University–sponsored quality improvement project aimed at enhancing car…
-
CLINICAL_TRIALS trial_result · 2025-09-11Clinical Trial Update: Combining HIIT and n-3 PUFA to Reduce Inflammation and Improve Metabolic Health [NA]
Completed study evaluating the combined effect of high-intensity interval training and omega-3 fatty acid supplementation on inflammation an…
-
CLINICAL_TRIALS withdrawal · 2025-09-11Clinical Trial Update: Combining HIIT and n-3 PUFA Supplementation to Reduce Inflammation and Improve Metabolic Health (HIIT&PUFA) [NA]
The HIIT&PUFA trial examining high-intensity interval training plus omega-3 fatty acid supplementation for obesity-related inflammation and …
-
CLINICAL_TRIALS research · 2025-08-24Clinical Trial Update: Evaluation of Dyslipidemia Management After Statin and Ezetimibe Complex Treatment
This clinical trial evaluates dyslipidemia management after a statin and ezetimibe complex therapy. The study is currently active but not re…
-
CLINICAL_TRIALS research · 2025-08-22Clinical Trial Update: Effects of a Digital Health Application (Lipodia) on LDL-cholesterol Levels [NA]
A clinical trial is investigating the effect of the Lipodia digital health application on LDL-cholesterol levels in individuals with hyperch…